Loading...

Nyxoah S.A.

NYXHNASDAQ
Healthcare
Medical - Instruments & Supplies
$6.43
$0.08(1.26%)

Nyxoah S.A. (NYXH) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Nyxoah S.A. (NYXH), covering cash flow, earnings, and balance sheets.

Revenue Growth
3.98%
3.98%
Operating Income Growth
-30.39%
30.39%
Net Income Growth
-37.08%
37.08%
Operating Cash Flow Growth
-9.93%
9.93%
Operating Margin
-1540.72%
1540.72%
Gross Margin
65.54%
65.54%
Net Profit Margin
-1597.50%
1597.50%
ROE
-64.70%
64.70%
ROIC
-58.50%
58.50%

Nyxoah S.A. (NYXH) Income Statement & Financial Overview

Review Nyxoah S.A. NYXH income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$1.06M$1.26M$1.27M$771000.00
Cost of Revenue$406000.00$335000.00$482000.00$281000.00
Gross Profit$658000.00$928000.00$784000.00$490000.00
Gross Profit Ratio$0.62$0.73$0.62$0.64
R&D Expenses$9.02M$11.75M$7.93M$7.47M
SG&A Expenses$12.03M$8.06M$7.71M$6.38M
Operating Expenses$21.30M$19.24M$15.76M$13.80M
Total Costs & Expenses$21.70M$19.57M$16.25M$14.08M
Interest Income$945000.00$829000.00$703000.00$2.07M
Interest Expense$694000.00$534000.00$672000.00$1.45M
Depreciation & Amortization$363000.00$216000.00$334000.00$660000.00
EBITDA-$21.20M-$18.09M-$15.88M-$11.24M
EBITDA Ratio-$19.93-$14.33-$12.54-$14.58
Operating Income-$20.64M-$18.31M-$14.98M-$13.31M
Operating Income Ratio-$19.40-$14.50-$11.83-$17.26
Other Income/Expenses (Net)-$1.62M$3.24M-$1.91M$624000.00
Income Before Tax-$22.26M-$15.07M-$16.89M-$12.68M
Income Before Tax Ratio-$20.92-$11.93-$13.34-$16.45
Income Tax Expense$125000.00$2.08M$173000.00$441000.00
Net Income-$22.38M-$17.15M-$17.06M-$13.12M
Net Income Ratio-$21.04-$13.58-$13.47-$17.02
EPS-$0.60-$0.46-$0.50-$0.43
Diluted EPS-$0.60-$0.46-$0.50-$0.43
Weighted Avg Shares Outstanding$37.43M$37.04M$34.38M$30.74M
Weighted Avg Shares Outstanding (Diluted)$37.43M$37.04M$34.38M$30.74M

Over the last four quarters, Nyxoah S.A. achieved steady financial progress, growing revenue from $771000.00 in Q2 2024 to $1.06M in Q1 2025. Gross profit stayed firm with margins at 62% in Q1 2025 versus 64% in Q2 2024. Operating income totaled -$20.64M in Q1 2025, maintaining a -1940% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$21.20M. Net income dropped to -$22.38M, with EPS at -$0.60. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;